WO2012062704A1 - Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2 - Google Patents

Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2 Download PDF

Info

Publication number
WO2012062704A1
WO2012062704A1 PCT/EP2011/069553 EP2011069553W WO2012062704A1 WO 2012062704 A1 WO2012062704 A1 WO 2012062704A1 EP 2011069553 W EP2011069553 W EP 2011069553W WO 2012062704 A1 WO2012062704 A1 WO 2012062704A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyrazol
pyrimidin
amino
amine
Prior art date
Application number
PCT/EP2011/069553
Other languages
English (en)
Inventor
Katie Ellard
Jeremy Major
Alison Jones
Rosemary Lynch
Nigel Ramsden
Original Assignee
Cellzome Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Limited filed Critical Cellzome Limited
Priority to CA2815330A priority Critical patent/CA2815330A1/fr
Priority to JP2013538147A priority patent/JP2014500254A/ja
Priority to EP11781515.9A priority patent/EP2638018A1/fr
Priority to AU2011328237A priority patent/AU2011328237A1/en
Priority to CN2011800645538A priority patent/CN103298794A/zh
Publication of WO2012062704A1 publication Critical patent/WO2012062704A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to a novel class of kinase inhibitors, including pharmaceutically acceptable salts, prodrugs and metabolites thereof, which are useful for modulating protein kinase activity for modulating cellular activities such as signal transduction, proliferation, and cytokine secretion. More specifically the invention provides compounds which inhibit, regulate and/or modulate kinase activity, in particular TYK2 activity, and signal transduction pathways relating to cellular activities as mentioned above. Furthermore, the present invention relates to pharmaceutical compositions comprising said compounds, for example for the treatment or prevention of an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease.
  • Protein kinases catalyze the phosphorylation of proteins, lipids, sugars, nucleosides and other cellular metabolites and play key roles in all aspects of eukaryotic cell physiology. Especially, protein kinases and lipid kinases participate in the signaling events which control the activation, growth, differentiation and survival of cells in response to extracellular mediators or stimuli such as growth factors, cytokines or chemokines. In general, protein kinases are classified in two groups, those that preferentially phosphorylate tyrosine residues and those that preferentially phosphorylate serine and/or threonine residues. The tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor (EGFR) and cytosolic non-receptor kinases such as Janus kinases (JAK).
  • EGFR epidermal growth factor receptor
  • JAK Janus kinases
  • Inappropriately high protein kinase activity is involved in many diseases including cancer, metabolic diseases, autoimmune or inflammatory disorders. This effect can be caused either directly or indirectly by the failure of control mechanisms due to mutation, overexpression or inappropriate activation of the enzyme. In all of these instances, selective inhibition of the kinase is expected to have a beneficial effect.
  • JAK Janus kinase
  • JAK3 Tyrosine kinase 2
  • TYK2 Tyrosine kinase 2
  • Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain.
  • the JAK proteins bind to cytokine receptors through their amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains.
  • JAKs are activated and phosphorylate the receptors, thereby creating docking sites for signalling molecules, especially for members of the signal transducer and activator of transcription (STAT) family (Yamaoka et al, 2004.
  • STAT signal transducer and activator of transcription
  • JAKs The Janus kinases (JAKs). Genome Biology 5(12): 253).
  • JAK1, JAK2 and TYK2 are ubiquitously expressed.
  • JAK3 is predominantly in hematopoietic cells and it is highly regulated with cell development and activation (Musso et al., 1995. J. Exp. Med. 181(4): 1425-31).
  • JAKl knockout mice display a perinatal lethal phenotype, probably related to the neurological effects that prevent them from sucking (Rodig et al, 1998. Cell 93(3):373-83). Deletion of the JAK2 gene results in embryonic lethality at embryonic day 12.5 as a result of a defect in erythropoiesis (Neubauer et al, 1998. Cell 93(3):397-409).
  • JAK3 deficiency was first identified in humans with autosomal recessive severe combined immunodeficiency (SCID) (Macchi et al, 1995. Nature 377(6544):65-68). JAK3 knockout mice too exhibit SCID but do not display non-immune defects, suggesting that an inhibitor of JAK3 as an immunosuppressant would have restricted effects in vivo and therefore presents a promising drug for immunosuppression (Papageorgiou and Wikman 2004, Trends in Pharmacological Sciences 25(11):558-62).
  • SCID autosomal recessive severe combined immunodeficiency
  • TYK2 The role of TYK2 in the biological response to cytokines was first characterized using a mutant human cell line that was resistant to the effects of Type I interferons (IFNs) and the demonstration that IFNa responsiveness could be restored by genetic complementation of TYK2 (Velazquez et al, 1992. Cell 70, 313-322). Further in vitro studies implicated TYK2 in the signaling pathways of multiple other cytokines involved in both innate and adaptive immunity. Analysis of TYK-2 7" mice however revealed less profound immunological defects than were anticipated (Karaghiosoff et al, 2000. Immunity 13, 549-560; Shimoda et al, 2000. Immunity 13, 561-671).
  • TYK2 deficient mice display merely reduced responsiveness to IFNa/ ⁇ and signal normally to interleukin 6 (IL-6) and interleukin 10 (IL- 10), both of which activate TYK2 in vitro.
  • IL-6 interleukin 6
  • IL- 10 interleukin 10
  • TYK2 was shown to be essential for IL-12 signaling with the absence of TYK2 resulting in defective STAT4 activation and the failure of T cells from these mice to differentiate into IFNy- producing Thl cells. Consistent with the involvement of TYK2 in mediating the biological effects of Type IFNs and IL-12, TYK2-/- mice were more susceptible to viral and bacterial infections.
  • HIES primary immunodeficiency hyper-IgE syndrome
  • An imbalance in T helper cell differentiation was also observed, with the patient's T cells exhibiting an extreme skew towards the development of IL-4 producing Th2 cells and impaired Thl differentiation.
  • cytokine signaling defects could be reponsible for many of the clinical manifestations described, for example atopic dermatitis and elevated IgE levels (enhanced Th2), increased incidence of viral infections (IFN defect), infection with intracellular bacteria (IL-12/Thl defect) and extracellular bacteria (IL-6 and IL-23/Thl7 defect).
  • IFN defect increased incidence of viral infections
  • IL-12/Thl defect infection with intracellular bacteria
  • IL-6 and IL-23/Thl7 defect extracellular bacteria
  • TYK2 variants are associated with protection against systemic lupus erythematosus (SLE) (TYK2 rs2304256 and rsl2720270, NASAdsson et al, 2005. Am. J. Hum. Genet. 76, 528-537; Graham et al., 2007. Rheumatology 46, 927-930; Hellquist et al, 2009. J. Rheumatol. 36, 1631-1638; Jarvinen et al, 2010. Exp. Dermatol. 19, 123-131) and multiple sclerosis (MS) (rs34536443, Ban et al, 2009. Eur. J. Hum. Genet. 17, 1309-1313; Mero et al, 2009.
  • SLE systemic lupus erythematosus
  • TYK2 plays essential roles in both innate and adaptive immunity.
  • a lack of TYK2 expression manifests in the attenuated signaling of multiple proinflammatory cytokines and a profound imbalance in T helper cell differentiation.
  • evidence from genetic association studies supports that TYK2 is a shared autoimmune disease susceptibility gene. Taken together, these reasons suggest TYK2 as a target for the treatment of inflammatory and auto-immune diseases.
  • JAK family inhibitors have been reported in the literature which may be useful in the medical field (Ghoreschi et al, 2009. Immunol Rev, 228:273-287). It is expected that a selective TYK2 inhibitor that inhibits TYK2 with greater potency than JAK2 may have advantageous therapeutic properties, because inhibition of JAK2 can cause anemia (Ghoreschi et al, 2009. Nature Immunol. 4, 356-360).
  • TYK2 inhibitors are described in European patent application with application N° 10168056.9.
  • Phenylaminopyrimidines as JAK2 kinase selective compounds are known from WO-A 2008/109943.
  • Pyrimidinyl-thiophene kinase modulators are known from WO-A 2007/053776.
  • TYK2 inhibitors are known from DE-A 102009001438, DE-A 102009015070 and WO-A 2011/113802.
  • an object of the present invention is to provide a new class of compounds as TYK2 inhibitors which preferably show selectivity over JAK2 and may be effective in the treatment or prophylaxis of disorders associated with TYK2.
  • R 1 is T 1 ; C(0)R 4 ; C(0)N(R 4a )R 4 ; or C(0)OR 4 ;
  • R 4 is T 1 ; or Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more R 5 , which are the same or different;
  • R a is H; or Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • R 5 is T 2 ; halogen; CN; C(0)OR 6 ; OR 6 ; C(0)R 6 ; C(0)N(R 6 R 6a ); S(0) 2 N(R 6 R 6a ); S(0)N(R 6 R 6a ); S(0) 2 R 6 ; S(0)R 6 ; N(R 6 )S(0) 2 N(R 6a R 6b ); N(R 6 )S(0)N(R 6a R 6b ); SR 6 ; N(R 6 R 6a ); OC(0)R 6 ; N(R 6 )C(0)R 6a ; N(R 6 )S(0) 2 R 6a ; N(R 6 )S(0)R 6a ; N(R 6 )C(0)N(R 6a R 6b ); N(R 6 )C(0)OR 6a ; or OC(0)N(R 6 R 6a );
  • R 8°, R 8°s d , R 8 o b u are independently selected from the group consisting of H; T 2 ; or Ci-6 alkyl, wherein Ci-6 alkyl is optionally substituted with one or more R 10 , which are the same or different;
  • R 9 is T 2 ; halogen; CN; C(0)OR 8c ; OR 8c ; C(0)R 8c ; C(0)N(R 8c R 8d ); S(0) 2 N(R 8c R 8d ); S(0)N(R 8c R 8d ); S(0) 2 R 8c ; S(0)R 8c ; N(R 8c )S(0) 2 N(R 8d R 8e ); N(R 8c )S(0)N(R 8d R 8e ); SR 8c ; N(R 8c R 8d ); OC(0)R 8c ; N(R 8c )C(0)R 8d ; N(R 8c )S(0) 2 R 8d ; N(R 8c )S(0)R 8d ; N(R 8c )C(0)N(R 8d R 8e ); N(R 8c )C(0)OR 8d ; and OC(0)N(R 8c R 8d );
  • R 8c , R 8d , R 8e are independently selected from the group consisting of H; T 2 ; or Ci-6 alkyl, wherein Ci-6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • T 2 is phenyl; C3-7 cycloalkyl; or 4 to 7 membered heterocyclyl, wherein T 2 is optionally substituted with one or more R 11 , which are the same or different;
  • R 12 , R 12a , R 12b , R 14 , R 14a , R 14b are independently selected from the group consisting of H; and Ci-6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more halogen, which are the same or different;
  • X 1 is N and X 2 is C(R 15 ); or X 1 is C(R 16 ) and X 2 is C(R 15 ); or X 1 is N and X 2 is N;
  • R 15 is C(R 17 ) 3 ;
  • R 2 is phenyl; or 4 to 7 membered aromatic heterocyclyl, wherein R 2 is optionally substituted with one or more R 18 , which are the same or different;
  • R 18 is T 3 ; halogen; CN; C(0)OR 19 ; OR 19 ; C(0)R 19 ; C(0)N(R 19 R 19a ); S(0) 2 N(R 19 R 19a ); S(0)N(R 19 R 19a ); S(0) 2 R 19 ; S(0)R 19 ; N(R 19 )S(0) 2 N(R 19a R 19b ); N(R 19 )S(0)N(R 19a R 19b ); SR 19 ; N(R 19 R 19a ); OC(0)R 19 ; N(R 19 )C(0)R 19a ; N(R 19 )S(0) 2 R 19a ; N(R 19 )S(0)R 19a ; N(R 19 )C(0)N(R 19a R 19b ); N(R 19 )C(0)OR 19a ; OC(0)N(R 19 R 19a ); or Ci -6 alkyl, wherein Ci -6 alkyl is optionally substituted with one or more R 20 , which are the same or different;
  • R 19 , R 19a , R 19b are independently selected from the group consisting of H; T 3 ; or Ci_6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more R 21 , which are the same or different;
  • T 3 is phenyl; C 3-7 cycloalkyl; or 4 to 7 membered heterocyclyl, wherein T 3 is optionally substituted with one or more R 22 , which are the same or different;
  • R , R are independently selected from the group consisting of halogen; CN; C(0)OR ; OR 25 ; C(0)R 25 ; C(0)N(R 25 R 25a ); S(0) 2 N(R 25 R 25a ); S(0)N(R 25 R 25a ); S(0) 2 R 25 ; S(0)R 25 ; N(R 25 )S(0) 2 N(R 25a R 25b ); N(R 25 )S(0)N(R 25a R 25b ); SR 25 ; N(R 25 R 25a ); OC(0)R 25 ; N(R 25 )C(0)R 25a ; N(R 25 )S(0) 2 R 25a ; N(R 25 )S(0)R 25a ; N(R 25 )C(0)N(R 25a R 25b ); N(R 25 )C(0)OR 25a ; and OC(0)N(R 25 R 25a );
  • R 23 , R 23a , R 23b , R 25 , R 25a , R 25b are independently selected from the group consisting of H; T 4 ; and Ci- 6 alkyl, wherein Ci_6 alkyl is optionally substituted with one or more R 26 , which are the same or different;
  • T 4 is phenyl; C3 -7 cycloalkyl; or 4 to 7 membered heterocyclyl, wherein T 4 is optionally substituted with one or more R 27 , which are the same or different;
  • 26 29 are independently selected from the group consisting of halogen; CN; C(0)OR 30 ; OR 30 ; C(0)R 30 ; C(O)N(R 30 R 30a ); S(O) 2 N(R 30 R 30a ); S(O)N(R 30 R 30a ); S(0) 2 R 30 ; S(0)R 30 ; N(R 30 )S(O) 2 N(R 30a R 30b ); N(R 30 )S(O)N(R 30a R 30b ); SR 30 ; N(R 30 R 30a ); OC(0)R 3 °; N(R 30 )C(O)R 30a ; N(R 30 )S(O) 2 R 30a ; N(R 30 )S(O)R 30a ; N(R 30 )C(O)N(R 30a R 30b ); N(R 30 )C(O)OR 30a ; and OC(O)N(R 30 R 30a ); R , R 2 , R
  • Compound (1) is known from EP 1 654 706 A as compound [165-1].
  • Compound (2) is known from WO 2010/055077 A as compound A41.
  • Compound (3) is known from M.E. Swarbrick et al., Bioorganic & Medicinal Chemistry Letters 19 (2009), 4504-4508 as compound 40.
  • Compound (4) is known from GB 2 056 449 A as compound of example 5.
  • Compound (5) is described by the Chemical Abstracts Service with accession number 1185523-72-1.
  • Compound (6) is described by the Chemical Abstracts Service with accession number 861211-24-7.
  • variable or substituent can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
  • the terms are used as follows:
  • Alkyl means a straight-chain or branched hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent as further specified.
  • Ci-4 alkyl means an alkyl chain having 1 - 4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g.
  • Ci-6 alkyl means an alkyl chain having 1 - 6 carbon atoms, e.g. if present at the end of a molecule: C 1 -4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl; tert-butyl, n-pentyl, n-hexyl, or e.g.
  • C 3 - 7 cycloalkyl or "C 3 - 7 cycloalkyl ring” means a cyclic alkyl chain having 3 - 7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl.
  • cyloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  • Each hydrogen of a cycloalkyl carbon may be replaced by a substituent as further specified.
  • the term “C 3 - 5 cycloalkyl” or "C 3 - 5 cycloalkyl ring” is defined accordingly.
  • Halogen means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
  • Examples for a 4 to 7 membered heterocycles are azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyr
  • the term "4 to 7 membered aromatic heterocyclyl” or “4 to 7 membered aromatic heterocycle” refers to a 4 to 7 membered heterocyclic ring which is aromatic.
  • heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole.
  • Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given below, with all combinations of preferred substituent definitions being a subject of the present invention.
  • the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts.
  • substituents mentioned below independently have the following meaning. Hence, one or more of these substituents can have the preferred or more preferred meanings given below.
  • R 1 is T 1 ; or C(0)R 4 .
  • R 4 is T 1 .
  • T 1 is cyclopropyl; thiophenyl; isothiazolyl; or pyrazolyl, wherein T 1 is optionally substituted with one or more R 7 (preferably one R 7 ), which are the same or different.
  • R 1 is C(0)T 1
  • T 1 is C3 -7 cycloalkyl, wherein T 1 is optionally substituted with one or more R 7 (preferably unsubstituted), which are the same or different. More preferably, T 1 is cyclopropyl.
  • R is T 1
  • T 1 is 5 membered aromatic heterocyclyl, wherein T 1 is optionally substituted with one or more R 7 (preferably one R 7 ), which are the same or different.
  • T 1 is isothiazolyl; or pyrazolyl, wherein T 1 is optionally substituted with one or more R 7 , which are the same or different.
  • Preferabl T is , more preferably,
  • R is defined as indicated above.
  • T is cyclopropyl; or pyrazolyl, wherein T is unsubstituted or substituted with one or more R , which are the same or different.
  • R 7 is methyl; CH 2 CH 2 OR 8c ; CH 2 C(0)T 2 ; or CH 2 C(0)N(R 8c R 8d ).
  • R 7 is methyl; CH 2 CH 2 OR 8c or CH 2 C(0)T 2 .
  • R 8c is preferably H.
  • T 2 is preferably morpholin-4- yl; pyrrolidin-lyl or piperidin-l-yl.
  • R 8c and R 8d are preferably H or Ci-4 alkyl. More preferably, T 2 is morpholin-4-yl. More preferably, R 8c is H and R 8d is ethyl. Even more preferably, R 7 is methyl. Even more preferably, R 7 is CH 2 C(0)N(R 8c R 8d ).
  • R 15 is CH 3 .
  • R 3 is H.
  • R 2 is phenyl; pyridyl; pyrimidyl; pyrazolyl; oxadiazolyl; thiazolyl; or thiadiazolyl, wherein R 2 is substituted with one or more R 18 , which are the same or different. More preferably, R 2 is phenyl, wherein R 2 is substituted with one or more R 18 .
  • R 2 is substituted with one or two R 18 .
  • R 18 is halogen; CN; S(0) 2 N(R 19 R 19a ); S(0) 2 R 19 ; HS(0) 2 R 19a ; OR 19 ; C(0)N(R 19a R 19 ); SR 19 ; C 1-4 alkyl, unsubstituted or substituted with one or more halogen, which are the same or different; HC(0)R 19 ; or C(0)R 19 . More preferably, R 18 is halogen; OCH 3 ; S(0) 2 CH 3 ; HS(0) 2 CH 3 ; or CH 2 HS(0) 2 CH 3 .
  • R 18 is F; CI; CN; OR 19 ; S(0) 2 R 19 ; C M alkyl, unsubstituted or substituted with one R 20 ; S(0) 2 NHR 19 ; S(0) 2 N(CH 3 )R 19 ; NHS(0) 2 R 19 ; C(0)NHR 19 ; C(0)N(CH 3 )R 19 ; NHC(0)R 19 ; CF 3 ; SR 19 ; T 3 , optionally substituted with one substituent selected from the group consisting of methyl and NH 2 ; C(0)T 3 or S(0) 2 T 3 , wherein T 3 is optionally substituted with one substituent selected from the group consisting of methyl and methylcarbonyl; NHC(0)T 3 ; or NHC(0)NHR 19a .
  • R 18 is F; CI; CN; OH; OCi -4 alkyl; S(0) 2 -C M alkyl; C M alkyl; CH 2 S(0) 2 CH 3 ; S(0) 2 NH 2 ; S(0) 2 N(CH 3 ) 2 ; S(0) 2 NHCi -4 alkyl; NH 2 ; NHS(0) 2 CH 3 ; C(0)NH 2 ; C(0)NH-Ci -4 alkyl; C(0)N(CH 3 ) 2 ; NHC(0)CH 3 ; CF 3 ; SCH 3 ; cyclohexyloxy; hydroxy ethyloxy; hydroxy ethylaminocarbonyl; methoxyethyloxy; pyrrolidin- 1- ylcarbonylmethyloxy; aminocarbonylmethylaminocarbonyl; pyrrolidin- 1 -ylcarbonyl; morpholin-4-ylcarbonyl; cyclopentylaminocarbonyl; tetrahydrof
  • R 18 is F; methyl; ethyl; iso-propyl; OR 19 ; C(0)NHR 19 ; or S(0) 2 NHR 19 , wherein R 19 is methyl; ethyl; iso-propyl; propyl; or CH 2 CH 2 OH.
  • R 2 is F
  • R 18 is defined as indicated above.
  • Prodmgs of the compounds of the present invention are also within the scope of the present invention.
  • Prodrug means a derivative that is converted into a compound according to the present invention by a reaction with an enzyme, gastric acid or the like under a physiological condition in the living body, e.g. by oxidation, reduction, hydrolysis or the like, each of which is carried out enzymatically.
  • Examples of a prodrug are compounds, wherein the amino group in a compound of the present invention is acylated, alkylated or phosphorylated to form, e.g., eicosanoylamino, alanylamino, pivaloyloxymethylamino or wherein the hydroxyl group is acylated, alkylated, phosphorylated or converted into the borate, e.g.
  • Metabolites of compounds of formula (I) are also within the scope of the present invention.
  • metabolites refers to all molecules derived from any of the compounds according to the present invention in a cell or organism, preferably mammal.
  • the term relates to molecules which differ from any molecule which is present in any such cell or organism under physiological conditions.
  • the structure of the metabolites of the compounds according to the present invention will be obvious to any person skilled in the art, using the various appropriate methods.
  • tautomerism e.g. keto-enol tautomerism
  • the individual forms e.g. the keto and enol form
  • stereoisomers e.g. enantiomers, cis/trans isomers, conformers and the like.
  • isomers can be separated by methods well known in the art, e.g. by liquid chromatography. The same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials.
  • the compounds of formula (I) may exist in crystalline or amorphous form. Furthermore, some of the crystalline forms of the compounds of formula (I) may exist as polymorphs, which are included within the scope of the present invention. Polymorphic forms of compounds of formula (I) may be characterized and differentiated using a number of conventional analytical techniques, including, but not limited to, X-ray powder diffraction (XRPD) patterns, infrared (IR) spectra, Raman spectra, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and solid state nuclear magnetic resonance (ss MR).
  • XRPD X-ray powder diffraction
  • IR infrared
  • Raman spectra Raman spectra
  • DSC differential scanning calorimetry
  • TGA thermogravimetric analysis
  • ss MR solid state nuclear magnetic resonance
  • the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
  • the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • Compounds of the formula (I) which contain one or more basic groups i.e.
  • acids which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
  • suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
  • the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
  • the respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
  • the present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • the term "pharmaceutically acceptable” means that the corresponding compound, carrier or molecule is suitable for administration to humans.
  • this term means approved by a regulatory agency such as the EMEA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, preferably in humans.
  • the present invention furthermore includes all solvates of the compounds according to the invention.
  • JAK comprises all members of the JAK family (e.g. JAK1, JAK2, JAK3, and TYK2).
  • JAK1 or "JAK1 kinase” means "Janus kinase 1".
  • the human gene encoding JAK1 is located on chromosome lp31.3.
  • JAK2 or "JAK2 kinase” means "Janus kinase 2".
  • the human gene encoding JAK2 is located on chromosome 9p24.
  • the expression "JAK3” or “JAK3 kinase” means “Janus kinase 3".
  • the gene encoding JAK3 is located on human chromosome 19pl3.1 and it is predominantly in hematopoietic cells.
  • the expression “TYK2” or “TYK2 kinase” means “Protein-Tyrosine kinase 2”.
  • the JAK3 and TYK2 genes are clustered on chromosome 19pl3.1 and 19pl3.2, respectively.
  • compounds of the invention were tested for their selectivity for TYK2 over JAK2 kinases. As shown, all tested compounds bind TYK2 more selectively than, JAK2 (see table 9 below).
  • the compounds of the present invention as mentioned above are considered to be useful for the prevention or treatment of diseases and disorders associated with TYK2, for example immunological, inflammatory, autoimmune, or allergic disorders, transplant rejection, Graft-versus-Host-Disease or proliferative diseases such as cancer.
  • diseases and disorders associated with TYK2 for example immunological, inflammatory, autoimmune, or allergic disorders, transplant rejection, Graft-versus-Host-Disease or proliferative diseases such as cancer.
  • the compounds of the present invention are selective TYK2 inhibitors.
  • the compounds of the present invention may be further characterized by determining whether they have an effect on TYK2, for example on its kinase activity (Fridman et al 2010. J. Immunology 2010 184(9):5298-307).
  • the present invention provides pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient together with a pharmaceutically acceptable carrier, optionally in combination with one or more other pharmaceutical compositions.
  • “Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered orally.
  • Saline and aqueous dextrose are preferred carriers when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid carriers for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained- release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin. Such compositions will contain a therapeutically effective amount of the therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration.
  • a pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like one or more compounds of formula (I) not being the first compound in the composition or other JAK inhibitors.
  • Further bioactive compounds may be steroids, leukotriene antagonists, cyclosporine or rapamycin.
  • the compounds of the present invention or pharmaceutically acceptable salt(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order.
  • the two compounds must be stable and compatible with each other and the other components of the formulation.
  • they may be provided in any convenient formulation, conveniently in such manner as are known for such compounds in the art.
  • the compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of formula (I) is administered in combination with another drug or pharmaceutically active agent and/or that the pharmaceutical composition of the invention further comprises such a drug or pharmaceutically active agent.
  • drug or pharmaceutically active agent includes a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • Combined or “in combination” or “combination” should be understood as a functional coadministration, wherein some or all compounds may be administered separately, in different formulations, different modes of administration (for example subcutaneous, intravenous or oral) and different times of administration. The individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical compositions.
  • Suitable examples of pharmaceutically active agents which may be employed in combination with the compounds of the present invention and their salts for rheumatoid arthritis therapy include: immunosuppresants such as amtolmetin guacil, mizoribine and rimexolone; anti-T Fa agents such as etanercept, infliximab, Adalimumab, Anakinra, Abatacept, Rituximab; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subreum; interleukin 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as RD-101 (Aventis); interleukin 1 receptor antagonists such as anakinra; CD8 antagonists such as amiprilose hydrochloride; beta amyloid precursor
  • the treatment defined herein may be applied as a sole therapy or may involve, in addition to the compounds of the invention, conventional surgery or radiotherapy or chemotherapy.
  • the compounds of the invention can also be used in combination with existing therapeutic agents for the treatment proliferative diseases such as cancer. Suitable agents to be used in combination include:
  • antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like
  • cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as finasteride;
  • antioestrogens for example tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene
  • anti-invasion agents for example c-Src kinase family inhibitors like 4-(6-chloro- 2,3 - methylenedioxyanilino)-7- [2-(4-methylpiperazin- 1 -yl)ethoxy] -5 -tetrahydropyran- 4-yloxy- quinazoline (AZD0530) and N-(2-chloro-6-methylphenyl)-2- ⁇ 6-[4-(2- hydroxy ethyl)piperazin-l-yl]-2-methylpyrimidin- 4-ylamino ⁇ thiazole-5-carboxamide (dasatinib, BMS-354825), and metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function); (iv) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody trastuzumab [
  • antisense therapies for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense agent;
  • gene therapy approaches including approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
  • immunotherapeutic approaches including ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
  • cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage
  • the individual compounds of such combinations may be administered either sequentially in separate pharmaceutical compositions as well as simultaneously in combined pharmaceutical compositions.
  • the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
  • any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed.
  • tablets may be coated by standard aqueous or non-aqueous techniques.
  • Such compositions and preparations should contain at least 0.1 percent of active compound.
  • the percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
  • the active compounds can also be administered intranasally, for example, as liquid drops or spray.
  • the tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin.
  • a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as fatty oil.
  • tablets may be coated with shellac, sugar or both.
  • a syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
  • Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
  • Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention.
  • oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
  • compounds of formula (I) are administered orally.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
  • a therapeutically effective amount of a compound of the present invention will normally depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration.
  • an effective amount of a compound of formula (I) for the treatment of an inflammatory disease for example rheumatoid arthritis (RA) will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day.
  • the actual amount per day would usually be from 70 to 700 mg and this amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
  • An effective amount of a pharmaceutically acceptable salt, prodrug or metabolite thereof may be determined as a proportion of the effective amount of the compound of formula (I) per se. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.
  • the term "effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician.
  • therapeutically effective amount means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder.
  • the term also includes within its scope amounts effective to enhance normal physiological function.
  • Another aspect of the present invention is a compound of the present invention or a pharmaceutically acceptable salt thereof for use as a medicament as mentioned above.
  • Another aspect of the present invention is a compound of the present invention or a pharmaceutically acceptable salt thereof for use in a method of treating or preventing a disease or disorder associated with TYK2 as mentioned above.
  • a disease or disorder associated with TYK2 is defined as a disease or disorder where TYK2 is involved.
  • the diseases or disorder is associated with TYK2 is an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.
  • another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease of a transplant rejection or a Graft-versus host disease.
  • Inflammation of tissues and organs occurs in a wide range of disorders and diseases and in certain variations, results from activation of the cytokine family of receptors.
  • Exemplary inflammatory disorders associated with activation of TYK2 include, in a non-limiting manner, skin inflammation due radiation exposure, asthma, allergic inflammation and chronic inflammation.
  • the inflammatory disease is an eye disease.
  • Dry eye syndrome also known as keratoconjunctivitis sicca
  • dysfunctional tear syndrome Jackson, 2009. Canadian Journal Ophthalmology 44(4), 385-394
  • DES affects up to 10% of the population between the ages of 20 to 45 years, with this percentage increasing with age.
  • a wide variety of artificial tear products are available, these products provide only transitory relief of symptoms. As such, there is a need for agents, compositions and therapeutic methods to treat dry eye.
  • dry eye disorder is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface.” (Lemp, 2007. "The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92). Dry eye is also sometimes referred to as keratoconjunctivitis sicca.
  • the treatment of the dry eye disorder involves ameliorating a particular symptom of dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface.
  • Uveitis is the most common form of intraocular inflammation and remains a significant cause of visual loss.
  • Current treatments for uveitis employs systemic medications that have severe side effects and are globally immunosuppressive.
  • Clinically chronic progressive or relapsing forms of non-infectious uveitis are treated with topical and/or systemic corticosteroids.
  • macrolides such as cyclosporine and rapamycin are used, and in some cases cytotoxic agents such as cyclophosphamide and chlorambucil, and antimetabolites such as azathioprine, methotrexate, and leflunomide (Srivastava et al, 2010.
  • Uveitis Mechanisms and recent advances in therapy. Clinica Chimica Acta, doi: 10.1016/j .cca.2010.04.017).
  • Further eye diseases, combination treatments and route of administration are described for example in WO-A 2010/039939, which is hereby incorporated herein by reference.
  • an autoimmune disease is a disease which is at least partially provoked by an immune reaction of the body against own components, for example proteins, lipids or DNA.
  • organ-specific autoimmune disorders are insulin- dependent diabetes (Type I) which affects the pancreas, Hashimoto's thyroiditis and Graves' disease which affect the thyroid gland, pernicious anemia which affects the stomach, Cushing's disease and Addison's disease which affect the adrenal glands, chronic active hepatitis which affects the liver; polycystic ovary syndrome (PCOS), celiac disease, psoriasis, inflammatory bowel disease (IBD) and ankylosing spondylitis.
  • PCOS polycystic ovary syndrome
  • celiac disease celiac disease
  • psoriasis inflammatory bowel disease (IBD)
  • ankylosing spondylitis ankylosing spondylitis.
  • Type I diabetes ensues from the selective aggression of autoreactive T-cells against insulin secreting beta-cells of the islets of Langerhans.
  • the autoimmune disease is selected from the group consisting of rheumatoid arthritis (RA), inflammatory bowel disease (IBD; Crohns's disease and ulcerative colitis), psoriasis, systemic lupus erythematosus (SLE), and multiple sclerosis (MS).
  • RA rheumatoid arthritis
  • IBD inflammatory bowel disease
  • SLE systemic lupus erythematosus
  • MS multiple sclerosis
  • RA Rheumatoid arthritis
  • RA is a chronic progressive, debilitating inflammatory disease that affects approximately 1% of the world's population.
  • RA is a symmetric polyarticular arthritis that primarily affects the small joints of the hands and feet.
  • pannus In addition to inflammation in the synovium, the joint lining, the aggressive front of tissue called pannus invades and destroys local articular structures (Firestein 2003, Nature 423 :356-361).
  • IBD Inflammatory bowel disease
  • Crohn's disease involves most frequently the terminal ileum and colon, is transmural and discontinuous.
  • ulcerative colitis the inflammation is continuous and limited to rectal and colonic mucosal layers.
  • definitive classification of Crohn's disease or ulcerative colitis cannot be made and are designated 'indeterminate colitis.
  • Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Neutrophil-induced injuries may be prevented by the use of neutrophils migration inhibitors (Asakura et al., 2007, World J Gastroenterol. 13(15):2145-9).
  • Psoriasis is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis (Schon et al., 2005, New Engl. J. Med. 352: 1899-1912).
  • SLE Systemic lupus erythematosus
  • SLE is a chronic inflammatory disease generated by T cell- mediated B-cell activation, which results in glomerulonephritis and renal failure.
  • MS Multiple sclerosis
  • Transplant rejection includes, without limitation, acute and chronic allograft rejection following for example transplantation of kidney, heart, liver, lung, bone marrow, skin and cornea.
  • T cells play a central role in the specific immune response of allograft rejection.
  • Hyperacute, acute and chronic organ transplant rejection may be treated. Hyperacute rejection occurs within minutes of transplantation. Acute rejection generally occurs within six to twelve months of the transplant. Hyperacute and acute rejections are typically reversible where treated with immunosuppressant agents.
  • Chronic rejection characterized by gradual loss of organ function, is an ongoing concern for transplant recipients because it can occur anytime after transplantation.
  • GVDH a major complication in allogeneic bone marrow transplantation (BMT). GVDH is caused by donor T cells that recognize and react to recipient differences in the histocompatibility complex system, resulting in significant morbidity and mortality.
  • the disease or disorder associated with TYK2 is a proliferative disease, especially cancer as mentioned above.
  • Another aspect of the present invention is a compound or a pharmaceutically acceptable salt thereof of the present invention for use in a method of treating or preventing a proliferative disease, especially cancer.
  • Cancer comprises a group of diseases characterized by uncontrolled growth and spread of abnormal cells. All types of cancers generally involve some abnormality in the control of cell growth, division and survival, resulting in the malignant growth of cells. Key factors contributing to said malignant growth of cells are independence from growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis, and genome instability (Hanahan and Weinberg, 2000. The Hallmarks of Cancer. Cell 100, 57-70).
  • cancers are classified as hematological cancers (for example leukemias and lymphomas) and solid cancers such as sarcomas and carcinomas (for example cancers of the brain, breast, lung, colon, stomach, liver, pancreas, prostate, ovary).
  • hematological cancers for example leukemias and lymphomas
  • solid cancers such as sarcomas and carcinomas (for example cancers of the brain, breast, lung, colon, stomach, liver, pancreas, prostate, ovary).
  • the TYK2 inhibitors of the present invention may also be useful in treating certain malignancies, including skin cancer and hematological malignancy such as lymphomas and leukemias.
  • Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prophylaxis of diseases and disorders associated with TYK2.
  • Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease.
  • Yet another aspect of the present invention is the use of a compound of the present invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating or preventing a proliferative disease, especially cancer.
  • diseases and disorders associated with TYK2 are as defined above.
  • Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of diseases and disorders associated with TYK2, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt thereof.
  • Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof one or more conditions selected from the group consisting of an immunological, inflammatory, autoimmune, or allergic disorder or disease or a transplant rejection or a Graft-versus host disease, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt thereof.
  • Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need thereof a proliferative disease, especially cancer, wherein the method comprises the administration to said patient a therapeutically effective amount of a compound according to present invention or a pharmaceutically acceptable salt thereof.
  • diseases and disorders associated with TYK2 are as defined above.
  • treating or “treatment” is intended to refer to all processes, wherein there may be a slowing, interrupting, arresting, or stopping of the progression of a disease, but does not necessarily indicate a total elimination of all symptoms.
  • Exemplary routes for the preparation of compounds of the present invention are described below. It is clear to a practitioner in the art to combine or adjust such routes especially in combination with the introduction of activating or protective chemical groups.
  • a general route for the preparation of compounds according to present invention is outlined in Schemes 1 and 2.
  • NMR spectra were obtained on a Brucker dpx400.
  • LCMS (methods A and B) was carried out on an Agilent 1100 using a Gemini C18, 3 x 30 mm, 3 micron column. Solvents used were water and acetonitrile with 0.1% formic acid and with an injection volume of 3 Wavelengths were 254 and 210 nm.
  • LCMS method C was carried out on a Waters uPLC- SQD using the same solvents. Photodiode array detection was between 210 and 400 nm.
  • Methods D-G were carried out on an Agilent 1200 series HPLC with detection at 254 Water (with 0.07% TFA) and methanol were the solvents used.
  • N-(lH-pyrazol-4-yl)pyrimidin-2-amine (1.1 eq), alkyl chloride (leq) potassium carbonate (2eq), sodium iodide (catalytic) and ACN were heated to 80°C for 1 h. The mixture was cooled to rt and EtOAc then water were added. The organic phase was separated, washed with brine, dried (MgS0 4 ) and concentrated in vacuo to afford a yellow oil. Petrol was added and the resulting precipitate was separated by filtration to give the desired product as a white solid.
  • Phenylchloroformate (209 mg, 1.3 mmol) was added dropwise to a stirred mixture of 4-(4- aminophenyl)-5-methyl-N-(l-methyl-lH-pyrazol-4-yl)pyrimidin-2-amine (250 mg, 0.89 mmol, prepared according to Procedure I(i)) and NaHC0 3 (224 mg, 2. 7 mmol) in THF (10 mL) and the mixture was stirred at rt for 3 h.
  • Step (ii) A mixture of perfluorophenyl 4-bromobenzenesulfonate (3.3 g, 8.2 mmol), bis(pinacolato)diboron (2.29 g, 9.0 mmol), Pd(dppf)Cl 2 (669 mg, 0.82 mmol), dppf (454 mg, 0.82 mmol), and sodium acetate (4.0 g, 49 mmol) in dioxane (116 mL) was heated to reflux under a nitrogen atmosphere for 16 h. The reaction was then cooled and the solid precipitate removed by filtration. The filtrate was concentrated to give a crude product which was boiled in hexane (40 mL).
  • n-BuLi 2.0 M in hexane, 2.1 mL, 4.2 mmol
  • 2-bromopyridine 675 mg, 4.2 mmol
  • dry ether 15 mL
  • 2-chloro-5- methylpyrimidine 500 mg, 3.9 mmol
  • ether 30 mL
  • reaction was quenched by addition of water (100 mg) in THF (3 mL) and then DDQ (1.32 g, 5.8 mmol) in THF (5 mL) was added. The reaction was warmed to rt and stirred for a further 15 min. It was then cooled to 0°C and hexane (10 mL) was added followed by 3M aqueous sodium hydroxide (2.5 mL, 7.5 mmol).
  • N-methyl-4-aminopyrazole (62 mg, 0.64 mmol) and 12M HC1 (0.15 mL, 1.7 mmol) were added to a stirred solution of 2-chloro-5-methyl-4-(pyridin-2-yl)pyrimidine (lOOmg, 0.49 mmol), in IP A (3 mL) then the mixture was heated to 160°C for 45 min in a microwave reactor. The reaction was quenched by addition of water and made basic with sodium hydroxide solution.
  • Examples 20-219 are given in Table 7 together with an indication of the procedures used to prepare them. The order of events is not implied and a person skilled in the art would understand that more than one order of events could lead to the desired product.
  • the affinity matrix was washed two times with 15mL of lx DP buffer containing 0.2% P40 (IGEPAL® CA-630, Sigma, #13021) and then resuspended in lxDP buffer containing 0.2% P40 (3% beads slurry).
  • 5xDP buffer 250mM Tris-HCl pH 7.4, 25% Glycerol, 7.5mM MgCl 2 , 750mM NaCl, 5mM Na 3 V0 4 ; filter the 5xDP buffer through a 0.22 ⁇ filter and store in aliquots at -80°C.
  • the 5xDP buffer is diluted with H 2 0 to lxDP buffer containing ImM DTT and 25mM NaF.
  • test compounds were prepared in DMSO. In a 96 well plate 30 ⁇ . solution of diluted test compounds at 5mM in DMSO were prepared. Starting with this solution a 1 :3 dilution series (9 steps) was prepared. For control experiments (no test compound) a buffer containing 2% DMSO was used.
  • Molt4 cells (ATCC catalogue number CRL-1582) and Ramos cells (ATCC catalogue number CRL-1596) were grown in 1L Spinner flasks (Integra Biosciences, #182101) in suspension in RPMI 1640 medium (Invitrogen, #21875-034) supplemented with 10% Fetal Bovine Serum (Invitrogen) at a density between 0.15 x 10 6 and 1.2 x 10 6 cells/mL. Cells were harvested by centrifugation, washed once with 1 x PBS buffer (Invitrogen, #14190-094) and cell pellets were frozen in liquid nitrogen and subsequently stored at -80°C.
  • the supernatant was transferred to an ultracentrifuge (UZ)-polycarbonate tube (Beckmann, 355654) and spun for lhour at lOO.OOOg at 4°C (33.500 rpm in ⁇ 50.2, precooled). The supernatant was transferred again to a fresh 50mL falcon tube, the protein concentration was determined by a Bradford assay (BioRad) and samples containing 50mg of protein per aliquot were prepared. The samples were immediately used for experiments or frozen in liquid nitrogen and stored frozen at -80°C.
  • Cell lysate (approximately 50mg protein per plate) was thawed in a water bath at room temperature and then stored on ice. To the thawed cell lysate lxDP 0.8% NP40 buffer containing protease inhibitors (1 tablet for 25mL buffer; EDTA-free protease inhibitor cocktail; Roche Diagnostics 1873580) was added in order to reach a final protein concentration of lOmg/mL total protein. The diluted cell lysate was stored on ice.
  • Mixed Molt4/Ramos lysate was prepared by combining one volume of Molt4 lysate and two volumes of Ramos lysate (ratio 1 :2).
  • the filter plate was placed on top of a collection plate (Greiner bio-one, PP-microplate 96 well V-shape, 65120) and the beads were then eluted with 20 ⁇ , of sample buffer (100 mM Tris, pH 7.4, 4% SDS, 0.00025% bromophenol blue, 20% glycerol, 50 mM DTT).
  • sample buffer 100 mM Tris, pH 7.4, 4% SDS, 0.00025% bromophenol blue, 20% glycerol, 50 mM DTT.
  • the eluate was frozen quickly at -80°C and stored at -20°C.
  • the kinases in the eluates were detected and quantified by spotting on nitrocellulose membranes and using a first antibody directed against the kinase of interest and a fluorescently labelled secondary antibody (anti-rabbit IRDyeTM antibody 800 (Licor, # 926-32211).
  • the Odyssey Infrared Imaging system from LI-COR Biosciences (Lincoln, Iowa, USA) was operated according to instructions provided by the manufacturer (Schutz-Geschiller et al., 2004. Quantitative, two-color Western blot detection with infrared fluorescence. Published May 2004 by LI-COR Biosciences, www.licor.com).
  • the nitrocellulose membrane (BioTrace NT; PALL, #BTNT30R) was first blocked by incubation with Odyssey blocking buffer (LICOR, 927-40000) for 1 hour at room temperature. Blocked membranes were then incubated for 16 hours at the temperature shown in table 8 with the first antibody diluted in Odyssey blocking buffer (LICOR #927- 40000). Afterwards the membrane was washed twice for 10 minutes with PBS buffer containing 0.2% Tween 20 at room temperature. The membrane was then incubated for 60 minutes at room temperature with the detection antibody (anti-rabbit IRDyeTM antibody 800, Licor, # 926-32211) diluted in Odyssey blocking buffer (LICOR #927-40000).
  • the detection antibody anti-rabbit IRDyeTM antibody 800, Licor, # 926-32211
  • the membrane was washed twice for 10 minutes each with 1 x PBS buffer containing 0.2% Tween 20 at room temperature. Then the membrane was rinsed once with PBS buffer to remove residual Tween 20. The membrane was kept in PBS buffer at 4°C and then scanned with the Odyssey instrument. Fluorescence signals were recorded and analysed according to the instructions of the manufacturer.
  • Activity level ⁇ ⁇ 0.1 ⁇ ; 0.1 ⁇ ⁇ ⁇ ⁇ ; 1 ⁇ ⁇ 0 ⁇ 10 ⁇ ; D >10 ⁇ ).
  • Examples inhibited TYK2 with activity level A and JAK2 with activity level B 36, 37, 49, 50, 51, 53, 54, 58, 60, 61, 71, 72, 75, 76, 77, 79, 83, 84, 88, 89, 91, 93, 94, 95, 96, 106, 114, 116, 117, 118, 120, 124, 137, 144, 146, 152, 154, 158, 159, 166, 171, 175, 176, 178, 183, 184, 185, 187, 191, 192, 193, 195, 198, 202, 203, 204, 207, 208, 209, 216, 218, 219.
  • Examples inhibited TYK2 with activity level A and JAK2 with activity level C: 29, 35, 56, 59, 62, 64, 67, 85, 90, 92, 97, 98, 111, 115, 121, 122, 123, 125, 126, 129, 132, 133, 134, 135, 136, 138, 147, 148, 149, 150, 151, 153, 160, 161, 162, 163, 164, 167, 168, 172, 174, 179, 180, 181, 182, 188, 189, 190, 196, 206, 214, 215.

Abstract

La présente invention concerne des composés de formule (I), dans laquelle R1 à R3, X1, X2 ont la signification telle que citée dans la description et les revendications. Lesdits composés sont utiles en tant qu'inhibiteurs de TYK2 pour le traitement ou la prophylaxie de troubles immunologiques, inflammatoires, auto-immuns, allergiques et de maladies à médiation immunologique. L'invention concerne également des compositions pharmaceutiques contenant lesdits composés ainsi que leur utilisation en tant que médicaments.
PCT/EP2011/069553 2010-11-09 2011-11-07 Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2 WO2012062704A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2815330A CA2815330A1 (fr) 2010-11-09 2011-11-07 Composes de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
JP2013538147A JP2014500254A (ja) 2010-11-09 2011-11-07 Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
EP11781515.9A EP2638018A1 (fr) 2010-11-09 2011-11-07 Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
AU2011328237A AU2011328237A1 (en) 2010-11-09 2011-11-07 Pyridine compounds and aza analogues thereof as TYK2 inhibitors
CN2011800645538A CN103298794A (zh) 2010-11-09 2011-11-07 作为tyk2抑制剂的吡啶化合物及其氮杂类似物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190460 2010-11-09
EP10190460.5 2010-11-09

Publications (1)

Publication Number Publication Date
WO2012062704A1 true WO2012062704A1 (fr) 2012-05-18

Family

ID=43587413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/069553 WO2012062704A1 (fr) 2010-11-09 2011-11-07 Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2

Country Status (6)

Country Link
EP (1) EP2638018A1 (fr)
JP (1) JP2014500254A (fr)
CN (1) CN103298794A (fr)
AU (1) AU2011328237A1 (fr)
CA (1) CA2815330A1 (fr)
WO (1) WO2012062704A1 (fr)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013034238A1 (fr) * 2011-09-09 2013-03-14 Merck Patent Gmbh Dérivés de benzonitrile en tant qu'inhibiteurs de kinases
WO2013092854A1 (fr) 2011-12-23 2013-06-27 Cellzome Limited Dérivés de pyrimidine-2,4-diamine en tant qu'inhibiteurs de kinase
WO2013174895A1 (fr) 2012-05-24 2013-11-28 Cellzome Limited Analogues hétérocyclyle de pyrimidine comme inhibiteurs de tyk2
EP2696683A1 (fr) * 2011-04-12 2014-02-19 Alzheimer's Institute of America, Inc. Compositions et utilisations thérapeutiques d'inhibiteurs de la kinase epsilon liée à ikk et de la kinase 1 de liaison à tank
WO2014074660A1 (fr) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifnα
WO2014161046A1 (fr) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Méthodes de traitement de maladies caractérisées par une signalisation wnt excessive
WO2014205213A1 (fr) * 2013-06-19 2014-12-24 University Of Utah Research Foundation Analogues de (e)-n'-(1-phényléthylidène)benzohydrazide substitués servant d'inhibiteurs de l'histone déméthylase
WO2015089479A1 (fr) * 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
WO2017162604A1 (fr) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement de lentigos séniles
US9809577B2 (en) 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2018183112A1 (fr) * 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Composé hétérocyclique
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
WO2020119819A1 (fr) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
WO2020206588A1 (fr) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzyléthers et anilines de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
WO2020223431A1 (fr) 2019-04-30 2020-11-05 Celgene Corporation Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
CN111961037A (zh) * 2020-09-17 2020-11-20 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
WO2021027647A1 (fr) * 2019-08-09 2021-02-18 中国医药研究开发中心有限公司 Composé de pyrimidine substitué par hétérocyclyle ponté, son procédé de préparation et son utilisation pharmaceutique
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11130752B2 (en) 2018-09-25 2021-09-28 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
US20220002301A1 (en) * 2020-07-02 2022-01-06 Pfizer Inc. Aminopyrimidinyl derivatives
EP3944859A1 (fr) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Procédé de traitement des toxicités immunitaires induites par des inhibiteurs des points de contrôle immunitaire
AU2018246382B2 (en) * 2017-03-31 2022-06-16 Vivoryon Therapeutics N.V. Novel inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2023076161A1 (fr) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Agents de dégradation de tyk2 et leurs utilisations
EP4206196A1 (fr) * 2021-12-29 2023-07-05 Almirall S.A. Dérivés substitués de pyrimidine en tant qu'inhibiteurs tyk2
EP3990449A4 (fr) * 2019-06-28 2023-07-26 Guangzhou InnoCare Pharma Tech Co., Ltd. Composés hétérocycliques pour la médiation de l'activité de la tyrosine kinase 2
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TWI832361B (zh) 2021-08-06 2024-02-11 大陸商特科羅生物科技（成都）有限公司 具有高口服生物利用度的ｊａｋ抑制劑
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018003590A (es) * 2015-09-25 2018-11-29 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos y metodos para la inhibicion de jak.
CN106928216A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
EP3526222B1 (fr) * 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
CN106588885B (zh) * 2016-11-10 2019-03-19 浙江大学 2-取代芳环-嘧啶类衍生物及制备和应用
CN110330484B (zh) * 2019-07-18 2022-08-26 中国药科大学 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN110734428A (zh) * 2019-10-24 2020-01-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
CN110862380A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物
WO2023208244A1 (fr) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 Composé macrocyclique et son utilisation
WO2024041397A1 (fr) * 2022-08-22 2024-02-29 Hangzhou Highlightll Pharmaceutical Co., Ltd Inhibiteurs de jak1/jak2/tyk2 pour le traitement topique de maladies dermatologiques
WO2023151724A1 (fr) * 2023-05-19 2023-08-17 凌科药业(杭州)有限公司 Formes cristallines de dérivé pyrazolyl-amino-pyrimidinyle, et procédé de préparation et utilisation associés

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056449A (en) 1979-08-08 1981-03-18 Searle & Co 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides
WO1998035985A1 (fr) 1997-02-12 1998-08-20 The Regents Of The University Of Michigan Proteines-marqueurs pour le cancer du poumon et utilisation de ces dernieres
WO1999002166A1 (fr) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Utilisation de derives de colchinol comme agents de degradation vasculaire
WO2000047212A1 (fr) 1999-02-10 2000-08-17 Astrazeneca Ab Derives de quinazoline utilises comme inhibiteurs de l'angiogenese
WO2001032651A1 (fr) 1999-11-05 2001-05-10 Astrazeneca Ab Derives de quinazoline utilises en tant qu'inhibiteurs du facteur de croissance endotheliale vasculaire (vegf)
WO2001060814A2 (fr) 2000-02-15 2001-08-23 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO2002064586A2 (fr) * 2001-02-09 2002-08-22 Vertex Pharmaceuticals Incorporated Inhibiteurs heterocycliques de erk2 et leurs utilisations
WO2002083667A2 (fr) * 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases
WO2004016597A2 (fr) * 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
WO2004083203A1 (fr) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
EP1654706A1 (fr) 2003-08-05 2006-05-10 Koninklijke Philips Electronics N.V. Procedes de codage et de decodage video et dispositifs associes
WO2006134056A1 (fr) 2005-06-14 2006-12-21 Cellzome Ag Procede d'identification de nouveaux composes interagissant avec les enzymes
EP1754706A1 (fr) * 2004-05-21 2007-02-21 Banyu Pharmaceutical Co., Ltd. INHIBITEURS SÉLECTIFS CONTRE LES Cdk4 ET Cdk6 AYANT UN SQUELETTE D'AMINOTHIAZOLE
WO2007053776A1 (fr) 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophène
WO2007107318A1 (fr) 2006-03-21 2007-09-27 Novartis Ag Combinaisons
WO2007137867A1 (fr) 2006-06-01 2007-12-06 Cellzome Ag Procédés pour identifier des molécules interagissant avec la kinase zap-70 et pour purifier celle-ci
WO2008109943A1 (fr) 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Composés de phénylamino pyrimidine et utilisations de ces derniers
WO2009008992A2 (fr) 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Traitement anticancéreux en combinaison
WO2009064835A1 (fr) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines et 4-pyrazolyl-n-hétéroarylpyrimidin-2-amines en tant qu'inhibiteurs de janus kinase
WO2009155551A1 (fr) 2008-06-20 2009-12-23 Genentech, Inc. Composés triazolopyridine inhibiteurs de jak kinase et procédés
WO2010039939A1 (fr) 2008-10-02 2010-04-08 Incyte Corporation Inhibiteurs des janus kinases pour le traitement du syndrome de l’œil sec et autres maladies de l’œil
WO2010055077A1 (fr) 2008-11-13 2010-05-20 Bayer Cropscience Sa Dérivés de pyridyl-azinylamine substitués utilisés comme fongicides
DE102009001438A1 (de) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102009015070A1 (de) 2009-03-30 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2011113802A2 (fr) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Composés d'imidazopyridine, compositions et procédés d'utilisation

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2056449A (en) 1979-08-08 1981-03-18 Searle & Co 8-substituted-7-phenyl-1,2,4- triazolo[4,3-c] pyrimidine-5-amines and amides
WO1998035985A1 (fr) 1997-02-12 1998-08-20 The Regents Of The University Of Michigan Proteines-marqueurs pour le cancer du poumon et utilisation de ces dernieres
WO1999002166A1 (fr) 1997-07-08 1999-01-21 Angiogene Pharmaceuticals Ltd. Utilisation de derives de colchinol comme agents de degradation vasculaire
WO2000047212A1 (fr) 1999-02-10 2000-08-17 Astrazeneca Ab Derives de quinazoline utilises comme inhibiteurs de l'angiogenese
WO2001032651A1 (fr) 1999-11-05 2001-05-10 Astrazeneca Ab Derives de quinazoline utilises en tant qu'inhibiteurs du facteur de croissance endotheliale vasculaire (vegf)
WO2001060814A2 (fr) 2000-02-15 2001-08-23 Sugen, Inc. Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
WO2002064586A2 (fr) * 2001-02-09 2002-08-22 Vertex Pharmaceuticals Incorporated Inhibiteurs heterocycliques de erk2 et leurs utilisations
WO2002083667A2 (fr) * 2001-04-13 2002-10-24 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-jun n-terminal kinases (jnk) et d'autres proteines kinases
WO2004016597A2 (fr) * 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
WO2004083203A1 (fr) * 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
EP1654706A1 (fr) 2003-08-05 2006-05-10 Koninklijke Philips Electronics N.V. Procedes de codage et de decodage video et dispositifs associes
EP1754706A1 (fr) * 2004-05-21 2007-02-21 Banyu Pharmaceutical Co., Ltd. INHIBITEURS SÉLECTIFS CONTRE LES Cdk4 ET Cdk6 AYANT UN SQUELETTE D'AMINOTHIAZOLE
WO2006134056A1 (fr) 2005-06-14 2006-12-21 Cellzome Ag Procede d'identification de nouveaux composes interagissant avec les enzymes
WO2007053776A1 (fr) 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophène
WO2007107318A1 (fr) 2006-03-21 2007-09-27 Novartis Ag Combinaisons
WO2007137867A1 (fr) 2006-06-01 2007-12-06 Cellzome Ag Procédés pour identifier des molécules interagissant avec la kinase zap-70 et pour purifier celle-ci
WO2008109943A1 (fr) 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Composés de phénylamino pyrimidine et utilisations de ces derniers
WO2009008992A2 (fr) 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Traitement anticancéreux en combinaison
WO2009064835A1 (fr) * 2007-11-16 2009-05-22 Incyte Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines et 4-pyrazolyl-n-hétéroarylpyrimidin-2-amines en tant qu'inhibiteurs de janus kinase
WO2009155551A1 (fr) 2008-06-20 2009-12-23 Genentech, Inc. Composés triazolopyridine inhibiteurs de jak kinase et procédés
WO2010039939A1 (fr) 2008-10-02 2010-04-08 Incyte Corporation Inhibiteurs des janus kinases pour le traitement du syndrome de l’œil sec et autres maladies de l’œil
WO2010055077A1 (fr) 2008-11-13 2010-05-20 Bayer Cropscience Sa Dérivés de pyridyl-azinylamine substitués utilisés comme fongicides
DE102009001438A1 (de) 2009-03-10 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102009015070A1 (de) 2009-03-30 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2011113802A2 (fr) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Composés d'imidazopyridine, compositions et procédés d'utilisation

Non-Patent Citations (39)

* Cited by examiner, † Cited by third party
Title
ASAKURA ET AL., WORLD J GASTROENTEROL., vol. 13, no. 15, 2007, pages 2145 - 9
BACON ET AL., PNAS, vol. 92, 1995, pages 7307 - 7311
BAN ET AL., EUR. J. HUM. GENET., vol. 17, 2009, pages 1309 - 1313
D'CRUZ ET AL., LANCET, vol. 369, no. 9561, 2007, pages 587 - 596
FIRESTEIN, NATURE, vol. 423, 2003, pages 356 - 361
FRIDMAN ET AL., J. IMMUNOLOGY, vol. 184, no. 9, 2010, pages 5298 - 307
GHORESCHI ET AL., IMMUNOL REV, vol. 228, 2009, pages 273 - 287
GHORESCHI ET AL., NATURE IMMUNOL, vol. 4, 2009, pages 356 - 360
GRAHAM ET AL., RHEUMATOLOGY, vol. 46, 2007, pages 927 - 930
HANAHAN, WEINBERG: "The Hallmarks of Cancer", CELL, vol. 100, 2000, pages 57 - 70
HELLQUIST ET AL., J. RHEUMATOL., vol. 36, 2009, pages 1631 - 1638
HEMMER ET AL., NAT. REV. NEUROSCIENCE, vol. 3, 2002, pages 291 - 301
J.C. BLAIS ET AL., INTERNATIONAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES, vol. 88, no. 1, 1989, pages 29 - 43
JACKSON, CANADIAN JOURNAL OPHTHALMOLOGY, vol. 44, no. 4, 2009, pages 385 - 394
JARVINEN ET AL., EXP. DERMATOL., vol. 19, 2010, pages 123 - 131
K. TAKAGI ET AL., CHIMICA THERAPEUTICA, vol. 9, no. 1, 1974, pages 14 - 18
KARAGHIOSOFF ET AL., IMMUNITY, vol. 13, 2000, pages 549 - 560
LEMP: "The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", THE OCULAR SURFACE, vol. 5, no. 2, 2007, pages 75 - 92
M.E. SWARBRICK ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 4504 - 4508
MACCHI ET AL., NATURE, vol. 377, no. 6544, 1995, pages 65 - 68
MERO ET AL., EUR. J. HUM. GENET., vol. 18, 2009, pages 502 - 504
MINEGISHI ET AL., IMMUNITY, vol. 25, 2006, pages 745 - 755
MUSSO ET AL., J. EXP. MED., vol. 181, no. 4, 1995, pages 1425 - 31
N. HEBERT ET AL., INTERNATIONAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES, vol. 79, 1986, pages 45 - 56
N. HEBERT ET AL., INTERNATIONNAL JOURNAL OF MASS SPECTROMETRY AND ION PROCESSES, vol. 79, 1986, pages 45 - 56
NEUBAUER ET AL., CELL, vol. 93, no. 3, 1998, pages 397 - 409
OYAMADA ET AL., J. IMMUNOL., vol. 183, 2009, pages 7539 - 7546
PAPAGEORGIOU, WIKMAN, TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 25, no. 11, 2004, pages 558 - 62
RODIG ET AL., CELL, vol. 93, no. 3, 1998, pages 373 - 83
SATO ET AL., J. CLIN. IMMUNOL., vol. 29, 2009, pages 815 - 825
SCHON ET AL., NEW ENGL. J. MED., vol. 352, 2005, pages 1899 - 1912
SHAW ET AL., PNAS, vol. 100, 2003, pages 11594 - 11599
SHIMODA ET AL., IMMUNITY, vol. 13, 2000, pages 561 - 671
SIGURDSSON ET AL., AM. J. HUM. GENET., vol. 76, 2005, pages 528 - 537
SPACH ET AL., J. IMMUNOL., vol. 182, 2009, pages 7776 - 7783
SRIVASTAVA ET AL.: "Uveitis: Mechanisms and recent advances in therapy", CLINICA CHIMICA ACTA, 2010
SWARBRICK M E ET AL: "Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2 pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 19, no. 15, 1 August 2009 (2009-08-01), pages 4504 - 4508, XP026301735, ISSN: 0960-894X, [retrieved on 20090226], DOI: DOI:10.1016/J.BMCL.2009.02.085 *
VELAZQUEZ ET AL., CELL, vol. 70, 1992, pages 313 - 322
YAMAOKA ET AL.: "The Janus kinases (JAKs", GENOME BIOLOGY, vol. 5, no. 12, 2004, pages 253

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2696683A4 (fr) * 2011-04-12 2014-08-13 Alzheimer S Inst Of America Inc Compositions et utilisations thérapeutiques d'inhibiteurs de la kinase epsilon liée à ikk et de la kinase 1 de liaison à tank
EP2696683A1 (fr) * 2011-04-12 2014-02-19 Alzheimer's Institute of America, Inc. Compositions et utilisations thérapeutiques d'inhibiteurs de la kinase epsilon liée à ikk et de la kinase 1 de liaison à tank
US9266838B2 (en) 2011-08-15 2016-02-23 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
US9642857B2 (en) 2011-08-15 2017-05-09 University Of Utah Research Foundation Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
US8969335B2 (en) 2011-09-09 2015-03-03 Merck Patent Gmbh Benzonitrile derivatives as kinase inhibitors
WO2013034238A1 (fr) * 2011-09-09 2013-03-14 Merck Patent Gmbh Dérivés de benzonitrile en tant qu'inhibiteurs de kinases
EA025038B1 (ru) * 2011-09-09 2016-11-30 Мерк Патент Гмбх Бензонитрильные производные в качестве ингибиторов киназ
WO2013092854A1 (fr) 2011-12-23 2013-06-27 Cellzome Limited Dérivés de pyrimidine-2,4-diamine en tant qu'inhibiteurs de kinase
CN104507929B (zh) * 2012-05-24 2018-02-16 赛尔佐姆有限公司 作为tyk2抑制剂的杂环基嘧啶类似物
RU2641895C2 (ru) * 2012-05-24 2018-01-23 Целльзом Лимитид ГЕТЕРОЦИКЛИЛЬНЫЕ ПИРИМИДИНОВЫЕ АНАЛОГИ В КАЧЕСТВЕ ИНГИБИТОРОВ Tук2
US20160184307A1 (en) * 2012-05-24 2016-06-30 Cellzome Limited Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors
CN104507929A (zh) * 2012-05-24 2015-04-08 赛尔佐姆有限公司 作为tyk2抑制剂的杂环基嘧啶类似物
US20150166513A1 (en) * 2012-05-24 2015-06-18 Cellzome Limited Heterocyclyl Pyrimidine Analogues As TYK2 Inhibitors
US9655897B2 (en) 2012-05-24 2017-05-23 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
WO2013174895A1 (fr) 2012-05-24 2013-11-28 Cellzome Limited Analogues hétérocyclyle de pyrimidine comme inhibiteurs de tyk2
US9296725B2 (en) 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
CN104781252A (zh) * 2012-11-08 2015-07-15 百时美施贵宝公司 用作IL-12、IL-23和/或IFNα应答调节剂的被烷基-酰胺取代的吡啶化合物
US9315494B2 (en) 2012-11-08 2016-04-19 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
TWI620737B (zh) * 2012-11-08 2018-04-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
EA028526B1 (ru) * 2012-11-08 2017-11-30 Бристол-Майерс Сквибб Компани АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα
WO2014074660A1 (fr) * 2012-11-08 2014-05-15 Bristol-Myers Squibb Company Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifnα
WO2014161046A1 (fr) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Méthodes de traitement de maladies caractérisées par une signalisation wnt excessive
WO2014205213A1 (fr) * 2013-06-19 2014-12-24 University Of Utah Research Foundation Analogues de (e)-n'-(1-phényléthylidène)benzohydrazide substitués servant d'inhibiteurs de l'histone déméthylase
US11572356B2 (en) 2013-12-11 2023-02-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
US10759783B2 (en) 2013-12-11 2020-09-01 Biogen Ma Inc. Biaryl inhibitors of Bruton'S tyrosine kinase
US9809577B2 (en) 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
US10081619B2 (en) 2013-12-11 2018-09-25 Biogen Ma Inc. Biaryl inhibitors of bruton's tyrosine kinase
US10633348B2 (en) 2013-12-13 2020-04-28 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2015089479A1 (fr) * 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10597387B2 (en) 2013-12-13 2020-03-24 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9856223B2 (en) 2013-12-13 2018-01-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10464949B2 (en) 2014-10-22 2019-11-05 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
US10844077B2 (en) 2014-10-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2017162604A1 (fr) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de traitement de lentigos séniles
TWI789381B (zh) * 2017-03-27 2023-01-11 美商卡都瑞恩醫藥有限責任公司 雜環化合物
US10543212B2 (en) 2017-03-27 2020-01-28 Cardurion Pharmaceuticals, Llc Substituted amines for treating cardiac diseases
WO2018183112A1 (fr) * 2017-03-27 2018-10-04 Cardurion Pharmaceuticals, Llc Composé hétérocyclique
US11197858B2 (en) 2017-03-27 2021-12-14 Cardurion Pharmaceuticals, Llc Substituted amines for treating cardiac diseases
AU2018246382B2 (en) * 2017-03-31 2022-06-16 Vivoryon Therapeutics N.V. Novel inhibitors
US11130752B2 (en) 2018-09-25 2021-09-28 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11866432B2 (en) 2018-10-11 2024-01-09 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020092015A1 (fr) 2018-11-02 2020-05-07 University Of Rochester Atténuation thérapeutique d'une infection épithéliale
US20240025882A1 (en) * 2018-12-14 2024-01-25 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolylamino- pyrimidinyl derivatives, and compositions and methods thereof
WO2020119819A1 (fr) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
EP3953347A4 (fr) * 2019-04-08 2023-01-18 Lynk Pharmaceuticals Co. Ltd. Benzyléthers et anilines de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
WO2020207414A1 (fr) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co. Ltd. Benzyléthers et anilines de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
WO2020206588A1 (fr) * 2019-04-08 2020-10-15 Lynk Pharmaceuticals Co., Ltd. Benzyléthers et anilines de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
WO2020223431A1 (fr) 2019-04-30 2020-11-05 Celgene Corporation Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
WO2020222773A1 (fr) 2019-04-30 2020-11-05 Celgene Corporation Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3990449A4 (fr) * 2019-06-28 2023-07-26 Guangzhou InnoCare Pharma Tech Co., Ltd. Composés hétérocycliques pour la médiation de l'activité de la tyrosine kinase 2
CN112654605A (zh) * 2019-08-09 2021-04-13 中国医药研究开发中心有限公司 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
WO2021027647A1 (fr) * 2019-08-09 2021-02-18 中国医药研究开发中心有限公司 Composé de pyrimidine substitué par hétérocyclyle ponté, son procédé de préparation et son utilisation pharmaceutique
US11427567B2 (en) 2019-08-14 2022-08-30 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11655252B2 (en) * 2020-07-02 2023-05-23 Pfizer Inc. Aminopyrimidinyl derivatives
US20220002301A1 (en) * 2020-07-02 2022-01-06 Pfizer Inc. Aminopyrimidinyl derivatives
WO2022023490A1 (fr) 2020-07-30 2022-02-03 Assistance Publique - Hôpitaux De Paris Procédé de traitement de toxicités immunitaires induites par des inhibiteurs de points de contrôle immunitaires
EP3944859A1 (fr) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Procédé de traitement des toxicités immunitaires induites par des inhibiteurs des points de contrôle immunitaire
CN111961037A (zh) * 2020-09-17 2020-11-20 嘉兴特科罗生物科技有限公司 一种作为jak激酶抑制剂的药物化合物
TWI832361B (zh) 2021-08-06 2024-02-11 大陸商特科羅生物科技（成都）有限公司 具有高口服生物利用度的ｊａｋ抑制劑
WO2023076161A1 (fr) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Agents de dégradation de tyk2 et leurs utilisations
EP4206196A1 (fr) * 2021-12-29 2023-07-05 Almirall S.A. Dérivés substitués de pyrimidine en tant qu'inhibiteurs tyk2

Also Published As

Publication number Publication date
JP2014500254A (ja) 2014-01-09
CN103298794A (zh) 2013-09-11
EP2638018A1 (fr) 2013-09-18
CA2815330A1 (fr) 2012-05-18
AU2011328237A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
EP2638018A1 (fr) Composés de pyridine et leurs analogues aza en tant qu'inhibiteurs de tyk2
US20130143915A1 (en) Triazolopyridines as tyk2 inhibitors
AU2012288892B2 (en) Heterocyclyl pyrimidine analogues as JAK inhibitors
CN104507929B (zh) 作为tyk2抑制剂的杂环基嘧啶类似物
AU2012357038B2 (en) Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US20120040955A1 (en) Fluoro substituted pyrimidine compounds as jak3 inhibitors
US20120172384A1 (en) Heterocyclylaminopyrimidines as kinase inhibitors
WO2007056221A2 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs de kinases
WO2013017480A1 (fr) Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
US20120172385A1 (en) Ortho substituted pyrimidine compounds as jak inhibitors
CA2969296A1 (fr) Derives de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
WO2012143320A1 (fr) Composés (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine comme inhibiteurs de la jak3
WO2013017479A1 (fr) Dérivés de pyrazolo[4,3-c]pyridine en tant qu'inhibiteurs de jak
RU2564419C1 (ru) Гетероциклические аналоги пиримидина в качестве ингибиторов jak
NZ720726A (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11781515

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011781515

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2815330

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013538147

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011328237

Country of ref document: AU

Date of ref document: 20111107

Kind code of ref document: A